Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Cater

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
The American Journal of Cardiology|February 24, 2009
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)Matti J Tikkanen, Ingar Holme, Nilo B Cater, et al.
Sleep & Breathing = Schlaf & Atmung|May 20, 2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trialBrian S Wojeck, Silvio E Inzucchi, Ian J Neeland, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|March 27, 2009
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL studyIngar Holme, Michael Szarek, Nilo B Cater, et al.
European Heart Journal|April 17, 2018
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trialMichael D Ezekowitz, Charles V Pollack, Jonathan L Halperin, et al.
Journal of the American College of Cardiology|January 20, 2010
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trialMatti J Tikkanen, Michael Szarek, Rana Fayyad, et al.
Diabetes, Obesity & Metabolism|December 19, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trialFrancesco Cosentino, Samuel Dagogo-Jack, Robert Frederich, et al.
Diabetes, Obesity & Metabolism|November 17, 2022
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozinKaren D Corbin, Samuel Dagogo-Jack, Christopher P Cannon, et al.
Kidney Diseases (Basel, Switzerland)|March 3, 2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV TrialDavid Z I Cherney, Robert Frederich, Richard E Pratley, et al.
Diabetes, Obesity & Metabolism|September 2, 2024
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CVVikas S Sridhar, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Circulation|August 22, 2022
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV TrialFrancesco Cosentino, Christopher P Cannon, Robert Frederich, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
The American Journal of Cardiology|February 24, 2009
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)Matti J Tikkanen, Ingar Holme, Nilo B Cater, et al.
Sleep & Breathing = Schlaf & Atmung|May 20, 2022
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trialBrian S Wojeck, Silvio E Inzucchi, Ian J Neeland, et al.
European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology|March 27, 2009
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL studyIngar Holme, Michael Szarek, Nilo B Cater, et al.
European Heart Journal|April 17, 2018
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trialMichael D Ezekowitz, Charles V Pollack, Jonathan L Halperin, et al.
Journal of the American College of Cardiology|January 20, 2010
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trialMatti J Tikkanen, Michael Szarek, Rana Fayyad, et al.
Diabetes, Obesity & Metabolism|December 19, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trialFrancesco Cosentino, Samuel Dagogo-Jack, Robert Frederich, et al.
Diabetes, Obesity & Metabolism|November 17, 2022
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozinKaren D Corbin, Samuel Dagogo-Jack, Christopher P Cannon, et al.
Kidney Diseases (Basel, Switzerland)|March 3, 2025
Cardiovascular and Renal Outcomes with Ertugliflozin by Baseline Use of Renin-Angiotensin-Aldosterone System Inhibitors or Diuretics, Including Mineralocorticoid Receptor Antagonist: Analyses from the VERTIS CV TrialDavid Z I Cherney, Robert Frederich, Richard E Pratley, et al.
Diabetes, Obesity & Metabolism|September 2, 2024
Effects of ertugliflozin on uric acid and gout-related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CVVikas S Sridhar, Francesco Cosentino, Samuel Dagogo-Jack, et al.
Circulation|August 22, 2022
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV TrialFrancesco Cosentino, Christopher P Cannon, Robert Frederich, et al.
Pageof 6